Cite
HARVARD Citation
Tesch, H. et al. (2019). Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial. International journal of cancer. 144 (4), pp. 877-885. [Online].